Files in this item
Perspective for precision medicine for tuberculosis
Item metadata
dc.contributor.author | Lange, Christoph | |
dc.contributor.author | Aarnoutse, Rob | |
dc.contributor.author | Chesov, Dumitru | |
dc.contributor.author | van Crevel, Reinout | |
dc.contributor.author | Gillespie, Stephen H. | |
dc.contributor.author | Grobbel, Hans-Peter | |
dc.contributor.author | Kalsdorf, Barbara | |
dc.contributor.author | Kontsevaya, Irina | |
dc.contributor.author | van Laarhoven, Arjan | |
dc.contributor.author | Nishiguchi, Tomoki | |
dc.contributor.author | Mandalakas, Anna | |
dc.contributor.author | Merker, Matthias | |
dc.contributor.author | Niemann, Stefan | |
dc.contributor.author | Köhler, Niklas | |
dc.contributor.author | Heyckendorf, Jan | |
dc.contributor.author | Reimann, Maja | |
dc.contributor.author | Ruhwald, Morten | |
dc.contributor.author | Sanchez-Carballo, Patricia | |
dc.contributor.author | Schwudke, Dominik | |
dc.contributor.author | Waldow, Franziska | |
dc.contributor.author | DiNardo, Andrew R. | |
dc.date.accessioned | 2020-10-09T15:30:19Z | |
dc.date.available | 2020-10-09T15:30:19Z | |
dc.date.issued | 2020-10-08 | |
dc.identifier | 270639831 | |
dc.identifier | a232f76c-f669-44ac-995f-6ef55416956a | |
dc.identifier | 85094095750 | |
dc.identifier | 000580529100001 | |
dc.identifier.citation | Lange , C , Aarnoutse , R , Chesov , D , van Crevel , R , Gillespie , S H , Grobbel , H-P , Kalsdorf , B , Kontsevaya , I , van Laarhoven , A , Nishiguchi , T , Mandalakas , A , Merker , M , Niemann , S , Köhler , N , Heyckendorf , J , Reimann , M , Ruhwald , M , Sanchez-Carballo , P , Schwudke , D , Waldow , F & DiNardo , A R 2020 , ' Perspective for precision medicine for tuberculosis ' , Frontiers in Immunology , vol. 11 , 566608 . https://doi.org/10.3389/fimmu.2020.566608 | en |
dc.identifier.issn | 1664-3224 | |
dc.identifier.other | Bibtex: 10.3389/fimmu.2020.566608 | |
dc.identifier.uri | https://hdl.handle.net/10023/20756 | |
dc.description | Funding: German Center for Infection Research (DZIF) Clinical TB TTU-TB 02.704. The publication of this article was supported by the Open Access Publication Fund of the Leibniz Association. | en |
dc.description.abstract | Tuberculosis is a bacterial infectious disease that is mainly transmitted from human to human via infectious aerosols. Currently, tuberculosis is the leading cause of death by an infectious disease world-wide. In the past decade, the number of patients affected by tuberculosis has increased by ~20 percent and the emergence of drug-resistant strains of Mycobacterium tuberculosis challenges the goal of elimination of tuberculosis in the near future. For the last 50 years, management of patients with tuberculosis has followed a standardized management approach. This standardization neglects the variation in human susceptibility to infection, immune response, the pharmacokinetics of drugs, and the individual duration of treatment needed to achieve relapse-free cure. Here we propose a package of precision medicine-guided therapies that has the prospect to drive clinical management decisions, based on both host immunity and M. tuberculosis strains genetics. Recently, important scientific discoveries and technological advances have been achieved that provide a perspective for individualized rather than standardized management of patients with tuberculosis. For the individual selection of best medicines and host-directed therapies, personalized drug dosing, and treatment durations, physicians treating patients with tuberculosis will be able to rely on these advances in systems biology and to apply them at the bedside. | |
dc.format.extent | 9 | |
dc.format.extent | 592947 | |
dc.language.iso | eng | |
dc.relation.ispartof | Frontiers in Immunology | en |
dc.subject | Precision medicine | en |
dc.subject | Tuberculosis | en |
dc.subject | Tailor-made regimen | en |
dc.subject | Mycobacterial genotypes | en |
dc.subject | Endotypes | en |
dc.subject | QR180 Immunology | en |
dc.subject | RM Therapeutics. Pharmacology | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject.lcc | QR180 | en |
dc.subject.lcc | RM | en |
dc.title | Perspective for precision medicine for tuberculosis | en |
dc.type | Journal item | en |
dc.contributor.institution | University of St Andrews. School of Medicine | en |
dc.contributor.institution | University of St Andrews. Sir James Mackenzie Institute for Early Diagnosis | en |
dc.contributor.institution | University of St Andrews. Centre for Biophotonics | en |
dc.contributor.institution | University of St Andrews. Biomedical Sciences Research Complex | en |
dc.contributor.institution | University of St Andrews. Infection and Global Health Division | en |
dc.contributor.institution | University of St Andrews. Global Health Implementation Group | en |
dc.contributor.institution | University of St Andrews. Gillespie Group | en |
dc.contributor.institution | University of St Andrews. Infection Group | en |
dc.identifier.doi | 10.3389/fimmu.2020.566608 | |
dc.description.status | Peer reviewed | en |
This item appears in the following Collection(s)
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.